Federal Register / Vol. 88, No. 187 / Thursday, September 28, 2023 / Notices 66861 

issues of data harmonization and 

linkage. 

2. Using RWD as part of the scientific 

paradigm, including open science, 

scientific rigor and reproducibility, and 

team science. NIH seeks broad input on 

the opportunities and challenges related 

to using RWD as part of the scientific 

process. 

(a) Approaches or methods for using 

RWD in collaborative teams and 

ensuring reproducibility. 

(b) How do researchers assess the 

validation and verification of RWD data 

that is used in research. 

(c) Appropriate open science practices 

and use of the FAIR principles (https:// 

www.nature.com/articles/sdata201618) 

for research using RWD and approaches 

for maximizing appropriate data sharing 

when expected by the NIH Policy for 

Data Management and Sharing (https:// 

sharing.nih.gov/data-management-andsharing-policy) or other policies. 

3. Administrative and logistical 

considerations for collecting, using, and 

sharing RWD for biomedical and 

behavioral research. NIH seeks broad 

input on the opportunities and 

challenges related to the process of 

acquiring, using, and making RWD 

available for biomedical and behavioral 

research, including: 

(a) Pros and cons of various 

approaches for obtaining RWD through 

algorithms, purchasing RWD through 

trusted parties, accessing RWD through 

secure enclaves, etc. 

(b) Considerations regarding 

licensing, costs, third party 

involvement, and restrictions for data 

use and sharing. 

(c) Availability/utility of emerging deidentification technologies and data 

storage/sharing considerations. 

4. Ethical considerations for using 

RWD for biomedical and behavioral 

research. NIH seeks broad input on the 

opportunities and challenges related to 

potential bioethical issues regarding the 

collection, use, and sharing of RWD, 

including: 

(a) Strategies for protecting 

participant privacy and autonomy. 

(b) Potential re-identification risks for 

RWD, including the technical feasibility 

of re-identifying linked data and the 

possibility of anonymity for patients, 

research participants, and their families. 

(c) Ethical implications of data as a 

‘‘commodity’’, in terms of buying and 

selling personal health data. 

This RFI is for planning purposes 

only and should not be construed as a 

solicitation for applications or 

proposals, or as an obligation in any 

way on the part of the United States 

Government. The Government will not 

pay for the preparation of any 

information submitted or for the 

Government’s use. Additionally, the 

Government cannot guarantee the 

confidentiality of the information 

provided. 

Dated: September 21, 2023. 

Tara A. Schwetz, 

Acting Principal Deputy Director, National 

Institutes of Health. 

[FR Doc. 2023–21239 Filed 9–27–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Establishment of the Social and 

Community Influences on Health 

Integrated Review Group 

Pursuant to the Federal Advisory 

Committee Act, as amended (5 U.S.C. 

1001–1014), the Director, National 

Institutes of Health (NIH) announces the 

establishment of the Social and 

Community Influences on Health 

Integrated Review Group (IRG) as 

authorized by 42 U.S.C. 282(b)(16), 

section 402(b)(16) of the Public Health 

Service Act, as amended. 

The Director, NIH, has determined 

that the Social and Community 

Influences on Health IRG is in the 

public interest in connection with the 

performance of duties imposed on NIH 

by law, and that these duties can best be 

performed through the advice and 

counsel of the committee. 

The committee provides advice and 

recommendations on funding 

applications and proposals, including 

but not limited to, the scientific and 

technical merit of applications for 

grants-in-aid for research, research 

training, or research-related grants and 

cooperative agreements, or contract 

proposals relating to scientific areas 

relevant to social, interpersonal, 

community, and cultural influences on 

health, development, and well-being 

across the life span. 

Inquiries may be directed to Claire 

Harris, Director, Office of Federal 

Advisory Committee Policy, Office of 

the Director, National Institutes of 

Health, 6701 Democracy Boulevard, 

Suite 1000, Bethesda, Maryland 20892 

(Mail code 4875), Telephone (301) 496– 

2123, or Claire.Harris@nih.gov. 

Dated: September 21, 2023. 

Lawrence A. Tabak, 

Acting NIH Director, National Institutes of 

Health. 

[FR Doc. 2023–21234 Filed 9–27–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the Board of Scientific 

Counselors, National Cancer Institute. 

This meeting will be a hybrid meeting 

held in-person and virtually and will be 

open to the public as indicated below 

with attendance limited to space 

available. Individuals who plan to 

attend in-person or view the virtual 

meeting and need special assistance or 

other reasonable accommodations, 

should notify the Contact Person listed 

below in advance of the meeting. The 

open session can be accessed from the 

NIH Videocast at the following link: 

http://videocast.nih.gov/. 

The meeting will be closed to the 

public as indicated below in accordance 

with the provisions set forth in sections 

552b(c)(6), title 5 U.S.C., as amended for 

the review, discussion, and evaluation 

of individual intramural programs and 

projects conducted by the National 

Cancer Institute, including 

consideration of personnel 

qualifications and performance, and the 

competence of individual investigators, 

the disclosure of which would 

constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Board of Scientific 

Counselors, National Cancer Institute. 

Date: November 13, 2023. 

Open: 10:00 a.m. to 10:30 a.m. 

Agenda: Remarks from the NCI Director. 

Closed: 10:30 a.m. to 4:00 p.m. 

Agenda: Personnel qualifications and 

performance, and competence of individual 

investigators. 

Name of Committee: Board of Scientific 

Counselors, National Cancer Institute. 

Date: November 14, 2023. 

Closed: 11:00 a.m. to 1:45 p.m. 

Agenda: Personnel qualifications and 

performance, and competence of individual 

investigators. 

Place: National Institute of Health, 

Building 31, C Wing, 6th Floor, Conference 

Room C, 9000 Rockville Pike, Bethesda, MD 

20892 (Hybrid Meeting). 

Contact Person: Brian E. Wojcik, Ph.D., 

Senior Review Administrator, Institute 

Review Office, Office of the Director, 

National Cancer Institute, National Institutes 

of Health, 9609 Medical Center Drive, Room 

3W414, Rockville, MD 20850, 240–276–5660, 

wojcikb@mail.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 


ddrumheller on DSK120RN23PROD with NOTICES1
66862 Federal Register / Vol. 88, No. 187 / Thursday, September 28, 2023 / Notices 

applicable, the business or professional 

affiliation of the interested person. 

In the interest of security, NIH has 

procedures at https://www.nih.gov/aboutnih/visitor-information/campus-accesssecurity for entrance into on-campus and offcampus facilities. All visitor vehicles, 

including taxicabs, hotel, and airport shuttles 

will be inspected before being allowed on 

campus. Visitors attending a meeting on 

campus or at an off-campus federal facility 

will be asked to show one form of 

identification (for example, a governmentissued photo ID, driver’s license, or passport) 

and to state the purpose of their visit. 

Information is also available on the 

Institute’s/Center’s home page: https://

deainfo.nci.nih.gov/advisory/bsc/index.htm, 

where an agenda and any additional 

information for the meeting will be posted 

when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: September 22, 2023. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–21147 Filed 9–27–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Diabetes and 

Digestive and Kidney Diseases; Notice 

of Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; NIDDK Specialized 

Study Centers Review. 

Date: October 30, 2023. 

Time: 10:00 a.m. to 1:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

NIDDK, Democracy II, Suite 7000A, 6707 

Democracy Boulevard, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Elena Sanovich, Ph.D., 

Scientific Review Officer, NIDDK/Scientific 

Review Branch, National Institutes of Health, 

6707 Democracy Blvd., Room 7351, 

Bethesda, MD 20892–2542, 301–594–8886, 

sanoviche@mail.nih.gov. 

Name of Committee: National Institute of 

Diabetes and Digestive and Kidney Diseases 

Special Emphasis Panel; Diabetes Self-Care. 

Date: November 3, 2023. 

Time: 10:00 a.m. to 11:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

NIDDK, Democracy II, Suite 7000A, 6707 

Democracy Boulevard, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Elena Sanovich, Ph.D., 

Scientific Review Officer, NIDDK/Scientific 

Review Branch, National Institutes of Health, 

6707 Democracy Blvd., Room 7351, 

Bethesda, MD 20892–2542, 301–594–8886, 

sanoviche@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.847, Diabetes, 

Endocrinology and Metabolic Research; 

93.848, Digestive Diseases and Nutrition 

Research; 93.849, Kidney Diseases, Urology 

and Hematology Research, National Institutes 

of Health, HHS) 

Dated: September 22, 2023. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–21153 Filed 9–27–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

NHLBI MOSAIC K99 R00 Review Panel. 

Date: November 3, 2023. 

Time: 12:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge I, 6705 Rockledge Drive, Bethesda, 

MD 20892 (Virtual Meeting). 

Contact Person: Kazuyo Kegan, Ph.D., 

Scientific Review Officer, Office of Scientific 

Review/DERA, National Heart, Lung, and 

Blood Institute, National Institutes of Health, 

6705 Rockledge Drive, Room 208–T, 

Bethesda, MD 20892, (301) 402–1334), 

kazuyo.kegan@nih.gov. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

NHLBI Mentored Career Development KAwards. 

Date: November 6, 2023. 

Time: 11:00 a.m. to 2:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge I, 6705 Rockledge Drive, Bethesda, 

MD 20892 (Virtual Meeting). 

Contact Person: Manoj K. Valiyaveettil, 

Ph.D., Scientific Review Officer, Blood & 

Vascular Branch, Office Scientific Review, 

Division of Extramural Research Activities 

(DERA), National Institute of Health, 

National Heart, Lung, and Blood Institute, 

Bethesda, MD 20817, (301) 402–1616, 

manoj.valiyaveettil@nih.gov. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

Grant Review for NHLBI K Award Recipients 

(R03). 

Date: November 9, 2023. 

Time: 10:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge I, 6705 Rockledge Drive, Bethesda, 

MD 20892 (Virtual Meeting). 

Contact Person: Zhihong Shan, Ph.D., MD, 

Scientific Review Officer, Office of Scientific 

Review/DERA, National Heart, Lung, and 

Blood Institute, National Institutes of Health, 

6705 Rockledge Drive, Room 205–J, 

Bethesda, MD 20892, (301) 827–7085, 

zhihong.shan@nih.gov. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

NHLBI Support for Conference and Scientific 

Meetings (R13). 

Date: November 16, 2023. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge I, 6705 Rockledge Drive, Bethesda, 

MD 20892 (Virtual Meeting). 

Contact Person: Kazuyo Kegan, Ph.D., 

Scientific Review Officer, Office of Scientific 

Review/DERA, National Heart, Lung, and 

Blood Institute, National Institutes of Health, 

6705 Rockledge Drive, Room 208–T, 

Bethesda, MD 20892, (301) 402–1334), 

kazuyo.kegan@nih.gov. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

Catalyze Product Definition (R61/R33). 

Date: November 16, 2023. 

Time: 10:00 a.m. to 4:00 p.m. 

Agenda: To review and evaluate grant 

applications. 


ddrumheller on DSK120RN23PROD with NOTICES1